Search Results - (Author, Cooperation:T. Haferlach)

2018-02-16

Nature Publishing Group (NPG)

2041-1723

Biology

Chemistry and Pharmacology

Natural Sciences in General

Physics

2011-09-13

Nature Publishing Group (NPG)

0028-0836

1476-4687

Biology

Chemistry and Pharmacology

Medicine

Natural Sciences in General

Physics

Alternative Splicing/genetics ; Exome/genetics ; Hematopoiesis/genetics ; Humans ; Mutation/*genetics ; Myelodysplastic Syndromes/*genetics ; Nuclear Proteins/genetics ; Polymorphism, Single Nucleotide/genetics ; RNA Splice Sites/genetics ; RNA Splicing/*genetics ; Ribonucleoproteins/genetics ; Spliceosomes/genetics

1432-1440

Acute promyelocytic leukemia ; Differentiation-inducing therapy ; 13-cis-retinoic acid ; All-trans-retinoic acid

Springer Online Journal Archives 1860-2000

Medicine

Summary The use of retinoic acid is a new approach in the treatment of acute promyelocytic leukemia. We outline the therapy in a 61-year-old patient with acute promyelocytic leukemia who had not responded to standard chemotherapy but in whom the administration of 13-cis-retinoic acid resulted in complete remission for 24 months. In relapse the patient was treated with all-trans-retinoic acid in combination with two cycles of daunorubicin and cytosine arabinoside and achieved another complete remission.

Electronic Resource

1432-1440

Multiple myeloma ; Prognostic factors ; Staging systems

Springer Online Journal Archives 1860-2000

Medicine

Summary For analysis of prognostic factors the clinical course of 109 patients with multiple myeloma was evaluated. Survival curves of immunoglobulin (Ig)G- and IgA-myelomas were identical (Fig. 1) with median survival times of 52 and 42 months, respectively, whereas patients with IgD- and Bence-Jones-myeloma had short survival times (median 3 months). Most important risk factors were anemia, renal insufficiency, and hypercalcemia (Figs. 7 and 8). Median survival time dropped from 52 months (Hb above 100 g/l) to 22 (Hb 85–100 g/l) and 1 month (Hb below 85 g/l). Patients with serum creatinine values below 2 mg/dl lived significantly longer than those with values above. Median survival times were 52 and 1 month, respectively. All seven hypercalcemic patients had a renal insufficiency and were in a very poor condition; their median survival time was 1 month. Analysis of the widely used staging system of Durie and Salmon [16] gave disappointing results. Survival curves of the three A-stages ran close together with median survival times of 58, 51, and 36 months. Only the A-B classification according to renal function (A: creatinine under 2 mg/dl; B: creatinine above 2 mg/dl) proved prognostically relevant.

Electronic Resource

1432-0584

Hodgkin's disease ; High-dose therapy ; Bone marrow transplantation

Springer Online Journal Archives 1860-2000

Medicine

Summary Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n=44), autologous BM plus peripheral blood stem cells (PBSC) (n=2), PBSC (n=1), syngeneic (n=1), or allogeneic BM (n=3). All patients had received standard salvage chemotherapy prior to HDT and were classified as sensitive (n=33) or resistant (n=17) to this treatment; one patient was in untreated relapse prior to BMT. The preparative regimens for patients receiving autologous BM and/or PBSC consisted of cyclophosphamide, VP 16, and BCNU (CVB) (n=44) or BCNU, etoposide, ara-C, and melphalan (BEAM) (n=3). The patients receiving allogeneic transplants were treated with the CVB regimen (n=2) or busulfan (16 mg/kg body wt.) and cyclophosphamide (200 mg/kg body wt.). With a median follow-up of 12 months, overall survival for 44 patients grafted with autologous BM is 61%±9%, progression-free survival for patients with sensitive disease is 44%±11%; no patient with resistant relapse survived beyond 1 year post transplant. Two of three patients grafted with allogeneic BM still survive 15 and 24 months after BMT with Karnofsky performance scores of 70% and 100%, respectively. The main toxicity encountered with the CVB regimen was interstitial pneumonia (IP), seen in four of 15 patients (27%) receiving ≥600 mg/m2 of BCNU. Three of these patients have died. The results show that HDT followed by hematopoietic stem cell rescue may effectively salvage an important fraction of patients with relapsed HD who respond to standard chemotherapy. The same approach is largely unsuccessful in patients with proven refractoriness to standard chemotherapy. Whether HDT followed by BMT or PBSC support is superior to intensive chemotherapy without stem cell support can be answered only by a prospectively randomized trial.

Electronic Resource

1432-0584

Acute myeloid leukemia ; Acute promyelocytic leukemia ; Acute myelomonocytic leukemia ; t (15, 17) ; inv(16)

Springer Online Journal Archives 1860-2000

Medicine

Summary Acute promyelocytic leukemia (AML FAB M3, APL) and acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) are considered distinct entities with characteristic clinical, morphological, cytogenetic, and prognostic features. Promyelocytic leukemia is characterized by abnormal promyelocytes replacing normal hematopoiesis associated with a translocation between the long arms of chromosomes 15 and 17 t (15; 17), severe coagulopathy, and responsiveness to all-trans retinoic acid (tretinoin). Characteristic features of AML M4Eo are a myelomonocytic marrow infiltration, eosinophils with abnormal immature granules positive for chloroacetate esterase, an inversion or translocation of chromosome 16, and an increased risk of meningeal relapses. Prognosis of both types of AML has been reported to be better than prognosis of the other entities combined. Since most of the published data were collected from heterogeneous patient populations treated with various chemotherapeutic regimens, we have analyzed treatment outcome of AML M3 and M4Eo in the AMLCG-85 study for patients younger than 60 years. For the total population of 594 patients of this study, CR rate was 68.89%, early death rate 11.60%, and no or partial remission was achieved in 19.51% of the cases. Of 40 patients with AML M3 or M3v complete remission was attained in 62.5%. Nine patients died within 42 days after the start of antileukemic therapy (22.5%). Of these nine, four died because of infection, five because of bleeding. Relapse-free survival rate was 59% after 3 years, significantly better than the respective curve of the other FAB types combined (35% after 3 years). In AML M4Eo, 91.7% of the 24 patients reached complete remission. The early death rate was 8.3%. No case of nonresponse was seen. Relapse-free survival rate was 49% after 3 years compared with 35% for the other types combined.

Electronic Resource

1432-1289

Schlüsselwörter Leberinfiltrate ; hämatologische Erkrankungen ; Leukämie ; Leberbefall ; M. Hodgkin ; Non-Hodgkin-Lymphome ; Hämoglobinopathien ; Leberbefunde ; Opportunistische Infektionen ; Leberbeteiligung

Springer Online Journal Archives 1860-2000

Medicine

Zum Thema Die Leber ist bei hämatologischen Erkrankungen ein häufig betroffenes Organ. Je nach Krankheitsentität findet sich in einem unterschiedlich hohen Anteil eine direkte Infiltration der Leber durch die malignen Zellen. Doch speziell bei den Leukämien und den myeloproliferativen Erkrankungen ist dies notwendigerweise nicht in jedem Einzelfall durch Leberbiopsie zu verifizieren, da therapeutische Konsequenzen zumeist nicht zu ziehen sind. Von weit größerer Relevanz ist jedoch – sowohl für die Therapie als auch für die Prognose – der Nachweis eines Leberbefalls bei den meisten Lymphomen und insbesondere beim M. Hodgkin. Dies muß deshalb bei der Diagnostik ggfs. durch Leberbiopsie geklärt werden. Darüber hinaus findet sich häufig eine Leberbeteiligung bei der Hämochromatose und bei Erkrankungen mit Veränderungen der Erythropoese. Gerade die dann beobachteten Parenchymveränderungen und Leberfunktionsstörungen geben zu therapeutischem Eingreifen Anlaß. Die heute vielfach in der Hämatologie und Onkologie verwendeten Chemotherapiekonzepte mit langanhaltenden Granulozytopenien führen nicht selten zu Infektionen der Leber. Ganz im Vordergrund stehen dabei Pilzinfektionen. Diese gilt es frühzeitig zu erkennen, damit die richtige kausale Therapie angesetzt werden kann.

Electronic Resource

2018-03-23

American Society of Hematology (ASH)

0006-4971

1528-0020

Biology

Medicine

Special Reports, Free Research Articles, Myeloid Neoplasia, Clinical Trials and Observations

2018-07-13

American Society of Hematology (ASH)

0006-4971

1528-0020

Biology

Medicine

Myeloid Neoplasia